Atlanta, Georgia, March 10, 2006

Contact: Robert Rhinehart
770-436-2480 or 404-683-2940

FOR IMMEDIATE RELEASE

Atlanta Biotech Company Achieves Success at International Conference

Atlanta biotech company CIS Biotech, Inc. was represented at the recent International Stroke Conference in Kissimmee, Florida, by its Management Team and a number of its scientific and medical advisors.

“We decided to participate in this conference,” commented Chairman and CEO Robert Rhinehart, “because CIS continues to be recognized as a company that is bringing a number of important tests to the market, of which both the medical profession and the public at large will benefit.”

Currently available as a “home brew”, Gold Dot 1 and Gold Dot 2 are CIS Biotech’s simple, inexpensive tests that detect precursors of stroke in the blood. Based on patents resulting from decades of international research, the tests, currently awaiting FDA approval, will, among other applications, be an important Emergency Room diagnostics tool. This point was emphasized by Dr. Ted Glynn of the Emergency Medicine Research Group of Lansing, Michigan, in a poster presentation at the conference.

CIS Biotech’s booth at the International Stroke Conference was visited by a large number of healthcare professionals, who expressed an interest in acquiring and using CIS’s technology in their institutions. The company already has a licensing agreement with the Diagnostics Division of Bayer HealthCare and is in discussion with others in the pharmacological industry. CIS Biotech also works closely with DeKalb Medical Center in Atlanta, where blood tests can be requested and public information is available.

Furthermore, an upcoming issue of the scientific/medical magazine “Stroke” will highlight CIS Biotech’s breakthrough tests.

CIS Biotech, Inc. is a Georgia corporation, established in 2000; its mission is to bring unique disease-associated biomarkers and in-vitro diagnostic (IVD) tools to the market, in order to solve unmet needs in risk assessment of stroke.